Author: Phelps, Christopher C.; Walker, Christopher M.; Honegger, Jonathan R.
Title: Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial Cord-id: ozsuv519 Document date: 2021_7_13
ID: ozsuv519
Snippet: Thirty years after its discovery, the hepatitis C virus (HCV) remains a leading cause of liver disease worldwide. Given that many countries continue to experience high rates of transmission despite the availability of potent antiviral therapies, an effective vaccine is seen as critical for the elimination of HCV. The recent failure of the first vaccine efficacy trial for the prevention of chronic HCV confirmed suspicions that this virus will be a challenging vaccine target. Here, we examine the
Document: Thirty years after its discovery, the hepatitis C virus (HCV) remains a leading cause of liver disease worldwide. Given that many countries continue to experience high rates of transmission despite the availability of potent antiviral therapies, an effective vaccine is seen as critical for the elimination of HCV. The recent failure of the first vaccine efficacy trial for the prevention of chronic HCV confirmed suspicions that this virus will be a challenging vaccine target. Here, we examine the published data from this first efficacy trial along with the earlier clinical and pre-clinical studies of the vaccine candidate and then discuss three key research directions expected to be important in ongoing and future HCV vaccine development. These include the following: 1. design of novel immunogens that generate immune responses to genetically diverse HCV genotypes and subtypes, 2. strategies to elicit broadly neutralizing antibodies against envelope glycoproteins in addition to cytotoxic and helper T cell responses, and 3. consideration of the unique immunological status of individuals most at risk for HCV infection, including those who inject drugs, in vaccine platform development and early immunogenicity trials.
Search related documents:
Co phrase search for related documents- acute infection and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
- acute infection and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36
- acute infection and adaptive immunity innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- acute infection and adenoviral vector: 1
- acute infection and adenovirus type: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute infection and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute infection and liver fibrosis: 1, 2, 3, 4, 5
- acute infection and long history: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute infection and longstanding infection: 1
- acute infection and low frequency: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute infection and lps stimulation: 1
- acute infection and lymph node: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute infection and macrophage monocyte: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- adaptive immune response and adenovirus type: 1, 2, 3
- adaptive immune response and adjuvant formulation: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date